Drug Profile
MM 09
Alternative Names: Dermatophagoides farinae/Dermatophagoides pteronyssinus allergen immunotherapy - Inmunotek; House dust mite allergen extract - Inmunotek; House dust mite allery immunotherapy D. pteronyssinus/D. farinae - Inmunotek; M-601/M-602; M-602/M-601; MM09; MM09-I/MM09-II; MM09-II/MM09-I; Polymerised-allergoids conjugated to nonoxidised- mannanLatest Information Update: 13 Dec 2022
Price :
$50
*
At a glance
- Originator Inmunotek
- Class Allergens; Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Allergic rhinitis; Asthma
- Phase II Hypersensitivity
Most Recent Events
- 13 Dec 2022 Inmunotek plans a phase II/III trial for Allergic rhinitis, Allergic asthma, Allergic rhinoconjunctivitis, Hypersensitivity (In Children, In adults) in Argentina (Sublingual) (NCT05641272)
- 02 Jun 2022 Inmunotek plans a phase III trial for Allergic asthma and Rhinitis/rhinoconjunctivitis (In child, In adult) in Spain (SC) in August 2022 (NCT05400811)
- 13 Oct 2021 Inmunotek intiates a phase III trial in Allergic rhinitis and Asthma in Spain (SC, PO, Sublingual) (EudraCT2021-003014-39)